Importantly, immediate reconstruction rates did not vary across HER2-positive, TNBC, or high-Ki-67 subgroups, indicating that our multidisciplinary workflow offered similar access to IBR regardless of tumor biology—a finding that contrasts with many North American and Asian reports, where aggressive subtypes often receive delayed reconstruction. The gene discussed is ERBB2; the disease is neoplasm.